Insider Sale: Director at $PDEX (PDEX) Sells 4,337 Shares
Insider Trading Activity: Raymond E Cabillot, a director at $PDEX, sold 4,337 shares of the company for approximately $193,907, representing about 1.3% of his holdings, while all recent insider trades in the past six months have been sales with no purchases.
Institutional Investor Movements: In the last quarter, 11 institutional investors increased their positions in $PDEX stock, whereas 8 reduced theirs, indicating mixed sentiment among larger shareholders.
Trade with 70% Backtested Accuracy
Analyst Views on PDEX
About PDEX
About the author
Pro-Dex Completes Acquisition of Advanced Precision Machining LLC
- Acquisition Completed: Pro-Dex announced the completion of its acquisition of Advanced Precision Machining LLC on February 9, 2026, which will enhance Pro-Dex's manufacturing capabilities in aerospace and defense systems, likely driving future revenue growth.
- Independent Operation: APM will operate independently from Pro-Dex, and due to its lengthy accounting close, future consolidated financial results are expected to be announced around statutory SEC deadlines, impacting Pro-Dex's financial transparency.
- Customer Expansion Plans: Pro-Dex aims to leverage APM's advanced automation technology to optimize its manufacturing and assembly processes in Irvine, building on a recently extended contract with its largest customer to enhance production efficiency and market competitiveness.
- Diverse Industry Services: As a Prime Contractor for the U.S. Government with ITAR and JCP certifications, Pro-Dex anticipates maintaining and expanding APM's business across other industries, thereby strengthening its market position and business diversification.
Pro-Dex Reports Q2 Earnings with Revenue of $1.9M
- Earnings Highlights: Pro-Dex reported a Q2 GAAP EPS of $0.66, with revenue at $1.9 million, indicating stable performance in the niche surgical tools market and reflecting its competitive position in this segment.
- Market Valuation: Pro-Dex is viewed as an attractive microcap despite customer risks, suggesting that its valuation may appeal to investors seeking undervalued opportunities in the market.
- Rating Analysis: Seeking Alpha's quantitative rating on Pro-Dex indicates a cautiously optimistic outlook from the market, highlighting investor interest in its potential growth, particularly in the surgical tools sector.
- Financial Transparency: The disclosure of financial information enhances investor confidence, as stable profitability, despite relatively low revenue, may lay the groundwork for future growth.
Pro-Dex (PDEX) Extends Major Customer Contract by Three Years, Anticipates Revenue Growth
- Contract Extension: Pro-Dex executed a contract amendment on December 17, 2025, with its largest customer, extending the agreement through December 31, 2028, which includes minimum purchase volumes, thereby positioning the company for sustained revenue growth over the next three years.
- Sales Performance Surge: For the fiscal first quarter ending September 30, 2025, Pro-Dex reported net sales of $18.5 million, a 24% increase from $14.9 million year-over-year, primarily driven by resumed shipments to its largest customer, indicating robust market demand.
- Net Income Growth: The company's net income rose to $4.7 million, or $1.40 per diluted share, compared to $2.5 million, or $0.75 per diluted share a year earlier, reflecting the successful launch and sales of its next-generation surgical handpiece.
- Optimistic Market Outlook: Pro-Dex anticipates that the extended contract will provide stability as it continues to innovate in surgical instrumentation and expand consulting services, further solidifying its position in the medical device market.
Investors May Worry About Pro-Dex's (NASDAQ:PDEX) Capital Returns
Pro-Dex's ROCE Performance: Pro-Dex has a return on capital employed (ROCE) of 21%, which is significantly higher than the industry average of 11%, indicating strong profitability relative to its capital employed.
Trends in Capital and Revenue: Although Pro-Dex's ROCE has decreased from 27% over the past five years, both revenue and capital employed have increased, suggesting the company is investing in growth.
Investment Potential: The stock has delivered a 1.8% gain to shareholders over the last five years, prompting a recommendation for further investigation into its investment potential.
Risks and Warnings: Despite its strong returns, Pro-Dex has been flagged with two warning signs in the investment analysis, indicating potential risks for investors.
Pro-Dex (NASDAQ:PDEX) Investors Celebrate Impressive 81% Return Over Three Years
Pro-Dex Share Performance: Pro-Dex, Inc. (NASDAQ:PDEX) saw a 29% drop in share price over the last quarter, but has gained 81% over the past three years, outperforming the market's 71% return during the same period.
Earnings Growth vs. Market Sentiment: Despite a compound earnings per share (EPS) growth of 38% per year, the average annual share price increase of 22% suggests that market sentiment towards Pro-Dex has cooled, as indicated by its low P/E ratio of 9.52.
Recent Performance and Investor Caution: Investors faced a total loss of 30% last year, contrasting with a market gain of 11%, raising concerns about unresolved challenges within the company, especially given its historical annualized loss of 3% over the past five years.
Investment Considerations: While the article encourages considering undervalued stocks, it also warns investors to be cautious and ensure they are investing in high-quality businesses, highlighting that Pro-Dex has two warning signs to be aware of.
Pro-Dex, Inc. (PDEX) Falls Short of Q4 Earnings and Revenue Projections
Earnings Performance: Pro-Dex, Inc. (PDEX) reported quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.47, and showing a decline from $0.46 per share a year ago. The company also posted revenues of $17.49 million, falling short of expectations by 2.27%.
Market Outlook: Pro-Dex shares have underperformed the market with a 0.6% loss since the beginning of the year, compared to the S&P 500's 9.6% gain. The company's Zacks Rank is currently #3 (Hold), indicating expected performance in line with the market, while the Medical - Dental Supplies industry is ranked in the bottom 30% of Zacks industries.
Pro-Dex Completes Acquisition of Advanced Precision Machining LLC
- Acquisition Completed: Pro-Dex announced the completion of its acquisition of Advanced Precision Machining LLC on February 9, 2026, which will enhance Pro-Dex's manufacturing capabilities in aerospace and defense systems, likely driving future revenue growth.
- Independent Operation: APM will operate independently from Pro-Dex, and due to its lengthy accounting close, future consolidated financial results are expected to be announced around statutory SEC deadlines, impacting Pro-Dex's financial transparency.
- Customer Expansion Plans: Pro-Dex aims to leverage APM's advanced automation technology to optimize its manufacturing and assembly processes in Irvine, building on a recently extended contract with its largest customer to enhance production efficiency and market competitiveness.
- Diverse Industry Services: As a Prime Contractor for the U.S. Government with ITAR and JCP certifications, Pro-Dex anticipates maintaining and expanding APM's business across other industries, thereby strengthening its market position and business diversification.
Pro-Dex Reports Q2 Earnings with Revenue of $1.9M
- Earnings Highlights: Pro-Dex reported a Q2 GAAP EPS of $0.66, with revenue at $1.9 million, indicating stable performance in the niche surgical tools market and reflecting its competitive position in this segment.
- Market Valuation: Pro-Dex is viewed as an attractive microcap despite customer risks, suggesting that its valuation may appeal to investors seeking undervalued opportunities in the market.
- Rating Analysis: Seeking Alpha's quantitative rating on Pro-Dex indicates a cautiously optimistic outlook from the market, highlighting investor interest in its potential growth, particularly in the surgical tools sector.
- Financial Transparency: The disclosure of financial information enhances investor confidence, as stable profitability, despite relatively low revenue, may lay the groundwork for future growth.
Pro-Dex (PDEX) Extends Major Customer Contract by Three Years, Anticipates Revenue Growth
- Contract Extension: Pro-Dex executed a contract amendment on December 17, 2025, with its largest customer, extending the agreement through December 31, 2028, which includes minimum purchase volumes, thereby positioning the company for sustained revenue growth over the next three years.
- Sales Performance Surge: For the fiscal first quarter ending September 30, 2025, Pro-Dex reported net sales of $18.5 million, a 24% increase from $14.9 million year-over-year, primarily driven by resumed shipments to its largest customer, indicating robust market demand.
- Net Income Growth: The company's net income rose to $4.7 million, or $1.40 per diluted share, compared to $2.5 million, or $0.75 per diluted share a year earlier, reflecting the successful launch and sales of its next-generation surgical handpiece.
- Optimistic Market Outlook: Pro-Dex anticipates that the extended contract will provide stability as it continues to innovate in surgical instrumentation and expand consulting services, further solidifying its position in the medical device market.
Investors May Worry About Pro-Dex's (NASDAQ:PDEX) Capital Returns
Pro-Dex's ROCE Performance: Pro-Dex has a return on capital employed (ROCE) of 21%, which is significantly higher than the industry average of 11%, indicating strong profitability relative to its capital employed.
Trends in Capital and Revenue: Although Pro-Dex's ROCE has decreased from 27% over the past five years, both revenue and capital employed have increased, suggesting the company is investing in growth.
Investment Potential: The stock has delivered a 1.8% gain to shareholders over the last five years, prompting a recommendation for further investigation into its investment potential.
Risks and Warnings: Despite its strong returns, Pro-Dex has been flagged with two warning signs in the investment analysis, indicating potential risks for investors.
Pro-Dex (NASDAQ:PDEX) Investors Celebrate Impressive 81% Return Over Three Years
Pro-Dex Share Performance: Pro-Dex, Inc. (NASDAQ:PDEX) saw a 29% drop in share price over the last quarter, but has gained 81% over the past three years, outperforming the market's 71% return during the same period.
Earnings Growth vs. Market Sentiment: Despite a compound earnings per share (EPS) growth of 38% per year, the average annual share price increase of 22% suggests that market sentiment towards Pro-Dex has cooled, as indicated by its low P/E ratio of 9.52.
Recent Performance and Investor Caution: Investors faced a total loss of 30% last year, contrasting with a market gain of 11%, raising concerns about unresolved challenges within the company, especially given its historical annualized loss of 3% over the past five years.
Investment Considerations: While the article encourages considering undervalued stocks, it also warns investors to be cautious and ensure they are investing in high-quality businesses, highlighting that Pro-Dex has two warning signs to be aware of.
Pro-Dex, Inc. (PDEX) Falls Short of Q4 Earnings and Revenue Projections
Earnings Performance: Pro-Dex, Inc. (PDEX) reported quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.47, and showing a decline from $0.46 per share a year ago. The company also posted revenues of $17.49 million, falling short of expectations by 2.27%.
Market Outlook: Pro-Dex shares have underperformed the market with a 0.6% loss since the beginning of the year, compared to the S&P 500's 9.6% gain. The company's Zacks Rank is currently #3 (Hold), indicating expected performance in line with the market, while the Medical - Dental Supplies industry is ranked in the bottom 30% of Zacks industries.
